Overview

“RVX-208 our lead compound from our NexVas PR platform is the first novel ApoA-I production small molecule to reach Phase 2b. We continue to engage in partnering discussions that will lead to the best value proposition for both Resverlogix and a leading pharmaceutical organization.”

Ken Lebioda, Senior VP Business & Corporate Development

Building a World Class Cardiovascular Disease Pipeline

We are engaged in active outreach to leading life science organizations. Our focus is to welcome the best ideas in science and build effective collaborations of every kind through to corporate licensing and acquisition of our leading technologies. We have worked with over 100 leading development organizations in the area of lipoprotein research. We continue to seek innovative partnering opportunities that provide a strategic fit to strengthen our product portfolio and deliver breakthrough medicines to improve people’s lives.